Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(5)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04547699Not ApplicableCompleted

Cytokines Supplementation to Culture Media and ICSI Outcome

Role: lead

NCT01790282Not ApplicableCompleted

Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT

Role: lead

NCT05423067Phase 1Completed

Permanent Occlusion of Uteine Arteies in Management of Abnormal Uterine Bleeding

Role: lead

NCT03040830Phase 4Completed

Effect of Timing Progesterone Luteal Support on Embryo Transfer

Role: lead

NCT02628756Not ApplicableCompleted

Endometrial Injury in Women With Unexplained Infertility

Role: lead

NCT01212263Not ApplicableCompleted

Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS

Role: lead

NCT01793038Not ApplicableUnknown

Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women

Role: lead

All 7 trials loaded